BlackRock Technology and Private Equity Term Trust

Brooklyn ImmunoTherapeutics, Inc. (BTX) is a clinical-stage biopharmaceutical company focused on advancing innovative therapies for cancer treatment, leveraging its proprietary technology platforms. Headquartered in Brooklyn, New York, the company is committed to addressing unmet medical needs in oncology through the development of both cellular and genetic therapies. With a strong emphasis on research and development, Brooklyn ImmunoTherapeutics aims to improve patient outcomes and enhance the quality of life for cancer patients internationally.